Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 24 Apr 2006 |
| Orion's Wholesale and Distribution Division to improve operational efficiency (part 2/2) | 24 Apr 2006 |
| Orion Corporation: 974,600 B-shares were subscribed with stock options 2001 in March 2006 | 4 Apr 2006 |
| President and CEO, Vice Chairman and Board Committees of Oriola-KD Corporation | 28 Mar 2006 |
| Kronans Droghandel AB?s President will resign | 24 Mar 2006 |